Skip to main content
. 2019 Mar 25;12:23. doi: 10.1186/s13041-019-0444-5

Fig. 1.

Fig. 1

The neuroprotective effects of osteocalcin (OCN) in rats with Parkinson’s disease (PD). OCN, administered either peripherally or centrally, ameliorates motor dysfunction, reduces dopaminergic neuronal loss and diminishes glia-mediated inflammatory responses in PD rat model induced by 6-OHDA via the AKT/GSK3β signaling pathway